UCB's Global Corporate Website

Welcome to UCB in the United States

Newsroom

Find U.S. news and updates from UCB, a global biopharmaceutical company focused on creating value for people living with severe diseases, such as epilepsy, Parkinson’s disease, psoriasis, osteoporosis, myasthenia gravis, rheumatoid arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, and more.

Spotlight Story

No results

UCB U.S. News

Nov 20, 2024

Closing gaps in HS care through community engagement and scientific innovation

Nov 20, 2024

UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F…

Nov 14, 2024

New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver…

Twitter Feed

For More Information

Speaker Requests

Connect with Us on Social

@UCBUSA Twitter

UCB USA YouTube